<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314300</url>
  </required_header>
  <id_info>
    <org_study_id>VERSATIS</org_study_id>
    <nct_id>NCT01314300</nct_id>
  </id_info>
  <brief_title>Lidocaine 5% Plasters (Versatis® 5%) in Pediatric Neuropathic Pains and Vasoocclusive Sickle Cell Crisis Pains</brief_title>
  <official_title>VERSATIS - Efficacy and Safety of Lidocaine 5% Plasters (Versatis® 5%) in Child, Adolescents and Young Adults With Neuropathic Pains or Vasoocclusive Sickle Cell Crisis Pains</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lidocaine 5% plaster (VERSATIS® 5%) showed its efficacy and safety in the post-herpetic&#xD;
      zoster adult pains. This treatment is recommended in first intention in adult neuropathic&#xD;
      pains with allodynia.&#xD;
&#xD;
      The purpose of this study is to assess efficacy and safety of lidocaine 5% plaster (VERSATIS®&#xD;
      5%) in the pediatric neuropathic pains and vasoocclusive sickle cell crises pains.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric neuropathic pain are infrequent. It's difficult to estimate the prevalence. It may&#xD;
      result from several causes : infectious (post-herpetic neuropathy), traumatic (tumor or&#xD;
      Positional)or toxic (chemotherapy or radiotherapy). They are often associated with malignant&#xD;
      pediatric disease.&#xD;
&#xD;
      These pains are spontaneous, continuous or intermittent, as type of burns or electric shocks&#xD;
      or abnormal skin sensation (hyperesthesia or allodynia). Treatment is the same as in adults:&#xD;
      antiepileptic or neuroleptics, sometimes associated with analgesic (level 2 or 3).&#xD;
&#xD;
      Lidocaine 5% plaster are used in adults as first line of treatment to reduce post-herpetic&#xD;
      neuropathic pain, especially in cases of mechanical allodynia. These plasters are indicated&#xD;
      for the symptomatic treatment of post-herpetic neuropathic pain.&#xD;
&#xD;
      Each plaster contains 700 mg of lidocaine. It must be applied on the painful area once daily&#xD;
      for a maximum period of 12 hours per 24 hours.&#xD;
&#xD;
      The primary endpoint is to evaluate the efficacy of lidocaine 5% plaster (VERSATIS 5%) after&#xD;
      12 hours on reducing of pure or mixed neuropathic pain and on reducing of vasoocclusive&#xD;
      sickle cell pain, localized, superficial, in child, adolescent and young adult.&#xD;
&#xD;
      The secondary endpoint are:&#xD;
&#xD;
        1. to evaluate the efficacy of lidocaine 5% plaster (VERSATIS 5%) after 6 hours on reducing&#xD;
           of pure or mixed neuropathic pain and on reducing of vasoocclusive sickle cell pain,&#xD;
           localized, superficial, in child, adolescent and young adult.&#xD;
&#xD;
        2. to evaluate safety of lidocaine 5% plaster (VERSATIS® 5%) in these same indications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lidocaine 5% plaster efficacy between t0 and t12</measure>
    <time_frame>12 hours</time_frame>
    <description>Rate of patients with a decrease of at least 2 points in pain score (at least 2 of 3 consecutive days) measured by self-assessment on a visual analogue scale (VAS) graded from 0 to 10 (0 = absence pain and 10 = maximal pain ), between start of treatment(t0) and a measure carried out 12 hours later (t12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lidocaine 5% plaster efficacy between t0 and t6</measure>
    <time_frame>6 hours</time_frame>
    <description>Rate of patients with a decrease of at least 2 points in pain score (at least 2 of 3 consecutive days) measured by self-assessment on a visual analogue scale (VAS) graded from 0 to 10 (0 = absence pain and 10 = maximal pain ), between start of treatment(t0) and a measure carried out 6 hours later (t6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lidocaine 5% plaster safety</measure>
    <time_frame>72 hours</time_frame>
    <description>Rate of patients with local and/or general adverse event as graded using NCI-CTCAE V4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Neuropathic Pains</condition>
  <condition>Vasoocclusive Sickle Cell Crises Pains</condition>
  <arm_group>
    <arm_group_label>Efficacy of Lidocaine 5% plaster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of pain by Lidocaine 5% plaster</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Lidocaine 5% plaster</description>
    <arm_group_label>Efficacy of Lidocaine 5% plaster</arm_group_label>
    <other_name>Versatis® 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  6 years &lt;= Age &lt;= 21 years&#xD;
&#xD;
          -  With:&#xD;
&#xD;
               -  Pure or mixed, localized, superficial neuropathic pains for which the neuropathic&#xD;
                  pain score DN4 is greater than or equal to 4&#xD;
&#xD;
               -  Or localized, superficial sickle cell crisis pains Insufficiently relieved by&#xD;
                  commonly used therapeutic (analgesic level II or III and / or antiepileptic&#xD;
                  drugs, and / or neuroleptics) - GCS &gt; 12&#xD;
&#xD;
          -  Covered by a medical insurance&#xD;
&#xD;
          -  Signed written informed consent form(for minors unemancipated, permission will be&#xD;
             given by holders of parental authority)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical condition not permitting data reporting (impaired consciousness)&#xD;
&#xD;
          -  Painful area with an surface greater than:&#xD;
&#xD;
               -  150 cm² for a patient with total body surface area &lt; 1 m²&#xD;
&#xD;
               -  300 cm² for a patient with 1 m² &lt; total body surface area &lt; 1.5 m²&#xD;
&#xD;
               -  450 cm² for a patient with total body surface area &gt; 1.5 m²&#xD;
&#xD;
          -  Existence of a statement for the use of lidocaine 5% (VERSATIS® 5%) plaster as defined&#xD;
             in the summary of product characteristics, as:&#xD;
&#xD;
               -  known hypersensitivity to the active substance or excipients&#xD;
&#xD;
               -  known hypersensitivity to other local anesthetics such as amide (eg bupivacaine,&#xD;
                  etidocaine, mepivacaine and prilocaine)&#xD;
&#xD;
               -  inflammatory or injured skin (active lesions of herpes zoster, dermatitis or&#xD;
                  wounds)&#xD;
&#xD;
          -  Severe cardiac insufficiency&#xD;
&#xD;
          -  Severe renal insufficiency&#xD;
&#xD;
          -  Severe hepatic insufficiency&#xD;
&#xD;
          -  Patient receiving anti-arrhythmic class I or other local anesthetics.&#xD;
&#xD;
          -  Pregnant or lactating female or female of child-bearing potential not employing&#xD;
             adequate contraception&#xD;
&#xD;
          -  Patient included in another clinical trial on the management of pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perrine MAREC-BERARD, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>IHOP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IHOP</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Médico-chirurgical de Réadaptation des Massues</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Walker SM. Pain in children: recent advances and ongoing challenges. Br J Anaesth. 2008 Jul;101(1):101-10. doi: 10.1093/bja/aen097. Epub 2008 Apr 21. Review.</citation>
    <PMID>18430745</PMID>
  </results_reference>
  <results_reference>
    <citation>Walco GA, Dworkin RH, Krane EJ, LeBel AA, Treede RD. Neuropathic pain in children: Special considerations. Mayo Clin Proc. 2010 Mar;85(3 Suppl):S33-41. doi: 10.4065/mcp.2009.0647. Review.</citation>
    <PMID>20194147</PMID>
  </results_reference>
  <results_reference>
    <citation>Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia. Drugs. 2009 Oct 22;69(15):2149-65. doi: 10.2165/11203220-000000000-00000. Review.</citation>
    <PMID>19791831</PMID>
  </results_reference>
  <results_reference>
    <citation>Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996 Apr;65(1):39-44. doi: 10.1016/0304-3959(95)00146-8.</citation>
    <PMID>8826488</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>March 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Child, adolescent, young adult</keyword>
  <keyword>Plaster</keyword>
  <keyword>Lidocaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

